iM Global Partner launches Eurozone multi-cap fund
It will be co-managed by seasoned portfolio managers
Régis Bégué is currently Partner of Zadig Asset Management and the co-manager of the Memnon European Equity Fund and has more than 29 years of experience. He joined Zadig in
The Zadig team believes in truly active management and focuses on high-conviction investments and opportunistic stock picking with a style-neutral approach. The fund will be built on a valuation-driven, bottom-up process and will have balanced exposure to cyclical, growth, defensive and financial themes, investing in those companies offering, what the Zadig team believes to be, are among the best risk/return profile.
The fund has a multi-cap, blend style and has a high focus on alpha generation. The current portfolio holds 40 stocks (and can go up to a maximum of 50). It will maintain a minimum of 50% exposure to large caps and a maximum of 50% exposure to mid caps with a significant focus on liquidity.
The fund will be SFDR[1] Article 8 and, for French investors, it will comply with the PEA (Plan d'Epargne en Actions) rules. Local registration for retail distribution is currently ongoing.
[1] SFDR Article 8 funds promote/integrate environmental and/or social characteristics and incorporate good governance practices into their investment strategy. More information on sustainability-related characteristics and/or objectives can be found here : https://www.imgp.com/en/sustainability.
Photo: https://mma.prnewswire.com/media/2583003/iM_Global_Partner.jpg
Logo: https://mma.prnewswire.com/media/1957526/iM_Global_Partner_Logo.jpg
CONTACT: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/im-global-partner-launches-eurozone-multi-cap-fund-302333664.html
SOURCE iM Global Partner
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX perpetual futures become Binance's No. 2 traded product; Binance captures over 60% market share across CEX and DEX venues
- Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P
- Hyperliquid Price Pulls Back 26% From $75 ATH While Pepeto Targets With $10.2M and a Listing
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share